This eBook series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the eBook series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The fourth volume of this series features 5 chapters that cover the following topics: - An overview of the incidence of neuraminadase resistance in influenza viruses in the Americas from 2004 to 2014 - Phenothiazines and derivative compounds for treating Trypanosoma cruzi infections - New antibacterial drug targets such as polysaccharide deacetylases - Improvements in aminoglycoside synthesis and biological activity (including RNA targeting) - A review of new chemotherapeutic agents against common infections.

This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The eighth volume of this series features 8 chapters that cover methods for antimicrobial drug discovery (with 2 chapters that focus on genomics) as well as updates on drug development against Helicobacter pylori and emerging coronaviruses, among other interesting topics: - Eradication of Helicobacter pylori Infection with Non-Bismuth Quadruple Concomitant Therapy - Drug Discovery Strategies Against Emerging Coronaviruses: A Global Threat - Opportunities Offered By Fragment-Based Drug Design in Antibiotic Development - Phage therapy as a Tool for Control of Foodborne Diseases: Advantages and Limitations - Subtractive Genomics Approaches: Towards Anti-Bacterial Drug Discovery - Recent Advances in the Discovery of Antimicrobials through Metagenomics - Phyto-Nano-Antimicrobials: Synthesis, Characterization, Discovery, and Advances - Aptamers as Anti-infective Agents.

This eBook series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the eBook series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The fifth volume of this series features 6 chapters that cover the following topics: - Virus infection pathways in living cells - Antimicrobial activity of natural products (essential oils and food products) - Medicinal plants that produce immunomodulators of veterinary interest - In silico approaches for determination of drug targets

This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The third volume of this series features 6 chapters that cover a variety of topics including: -Drug Discovery for TB -Therapeutic Limitations Due to Antibiotic Drug Resistance -Applications for Virus Vaccine Vectors in Infectious Disease Research -NewCastle Disease Virus -Anti-Infective Therapy Against Leishmaniasis -Anti-Viral Activity of Proanthocyanidins

Anti-infective agents are a distinct class of pharmacologically important molecules that have served mankind in different capacities to combat life-threatening pathological conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial, and urinary anti-infective agents. However, evolutionary changes, adaptations, and the development of new strains of pathogenic microorganisms have reduced the therapeutic efficacy of existing drugs, thus, limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 6 is a collection of notable research efforts, successful anti-infective drug development programs, and a comprehensive overview of successful and unsuccessful clinical trials conducted in this domain. This volume continues from the last one with interesting reviews on 1) “Reverse Vaccinology” for vaccination design using computational data to identify vaccine targets, 2) leptospirosis, 3) phage therapy for bacterial infections, 4) quorum sensing inhibitors from natural products, and 5) nitrogen and oxygen-based heterocyclic compounds that can act as anti-infective agents. The volume, therefore, covers a range of frontier topics on anti-infective research and development. This compilation is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

Anti-infective agents are a distinct class of pharmacologically important molecules that has served mankind in different capacities to combat life-threating pathologic conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial and urinary anti-infective agents. However, evolutionary changes, adaptations and development of pathogenic microorganisms strains the therapeutic efficacy of these drugs thus limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 5 is a collection of notable research efforts, successful anti-infective drug development programmes and a comprehensive overview of the successes and failures of recent clinical trials in this domain. The volume covers interesting topics: 1) the treatment of acute wounds with the vikut® formula, 2) anti-infective treatment of ocular diseases and 3) sars-cov vaccine development and antimicrobial therapy for SARS symptoms. A chapter summarizing recent anti-infective approaches rounds up the contents of this volume. This volume is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The ninth volume of this series features 5 reviews that cover some aspects of clinical and pre-clinical antimicrobial drug development, with 2 chapters focusing on drugs to treat leishmaniasis and dengue fever, respectively. - Use of preclinical and early clinical data for accelerating antimicrobial drug development - Post-translational modifications: host defence mechanism, pathogenic weapon, and emerged target of anti-infective drugs - Scope and limitations on the potent antimicrobial activities of hydrazone derivatives - Current scenario of anti-leishmanial drugs and treatment - Dengue hemorrhagic fever: the potential repurposing drugs